Pulmonary tuberculosis and tuberculous pleuropericarditis in a patient with pyoderma gangrenosum treated with adalimumab: a case report
Abstract
Background: Adalimumab is a tumor necrosis factor-α inhibitor, which is associated with an increased risk of tuberculosis. However, evidence regarding tuberculosis development in patients with pyoderma gangrenosum is limited, and simultaneous involvement in lungs, pleura, and pericardium is rare. This report describes a case of pulmonary tuberculosis and tuberculous pleuropericarditis associated with adalimumab administration.
Case presentation: The patient was a 59-year-old Filipino female. She began receiving adalimumab to treat pyoderma gangrenosum at the dermatology department of our hospital. The serum interferon-gamma release assay using QuantiFERON test, measured prior to administration, was negative. After five times of administration, she presented with fever, cough, and dyspnea. A chest computed tomography scan showed multiple small nodular shadows in the lung fields, right pleural effusion, and pericardial effusion. The administration of antibiotics and diuretics was ineffective. The QuantiFERON test was repeated, and was positive. The rapid sputum test for tuberculosis antigen was positive, and Mycobacterium tuberculosis was subsequently cultured 23 days later. Thus, she was diagnosed with pulmonary tuberculosis. Standard treatment with a combination of four antituberculous drugs was started, but drug susceptibility testing revealed resistance to isoniazid, so isoniazid was changed to levofloxacin. After treatment, multiple small nodular shadows in the lung…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Neuroprotective Effects of Epicatechin against Oxidative Stress-Induced Cognitive Impairment: A Systematic Review and Meta-Analysis
- Photochemical behavior of levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.